At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 11,016 enrolled
Drug / intervention
Ticagrelor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Transient Ischaemic Attack
In Brief
A Phase 3 clinical trial evaluating Ticagrelor and Placebo for Acute Ischaemic Stroke and Transient Ischaemic Attack. Completed, enrolled 11,016 participants across 387 sites in 28 countries.
Detailed Summary
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischaemic Stroke, Transient Ischaemic Attack
CountriesArgentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong, Hungary, India, Italy, Mexico, Peru, Poland, Romania, Russia, Saudi Arabia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartJan 2018
Primary CompletionDec 2019
TodayJul 2026
First PostedNov 28, 2017
Enrollment StartJan 22, 2018
Primary CompletionDec 13, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.6 years ago
Interventions
Ticagrelordrug
Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
Placebodrug
Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.